Ackrell Capital Cannabis Product Overview Lacks Investigative Leads
Summary
The passage is a marketing‑style description of cannabis product categories with no mention of individuals, transactions, government agencies, or wrongdoing. It provides no actionable leads for invest Describes capsules, tinctures, and topicals in the cannabis market. Includes branding and copyright notice from Ackrell Capital, LLC (FINRA/SIPC member). No references to political figures, financial
This document is from the House Oversight Committee Releases.
View Source CollectionPersons Referenced (2)
Tags
Related Documents (6)
Cannabis Investment Report – Ackrell Capital (Dec 2017) – Product Overview
The passage is a marketing‑style product description of cannabis flower and concentrates. It contains no references to political figures, government agencies, financial misconduct, or foreign influenc Describes cannabis flower characteristics and typical THC/CBD levels. Lists popular strain names and concentrate types. Claims 100% pesticide‑free product and FINRA/SIPC membership.
Ackrell Capital Cannabis Investment Report compares market size to alcohol, coffee, tobacco, and pharmaceuticals
The document is a commercial investment analysis with no mention of political figures, government agencies, or alleged misconduct. It offers no actionable leads for investigations and contains only pu Provides estimated penetration rates and consumer spending for cannabis versus other legal substance Claims U.S. legal cannabis market size aligns with other retail markets. Published by Ackrell Capi
Cannabis Investment Report – Private Company Funding Totals (2016‑2017 YTD)
The document lists aggregate capital raised by private cannabis‑related firms and a few deal specifics. It contains no references to high‑ranking officials, government agencies, foreign leaders, or al Total capital raised by private cannabis companies grew from $256 M in 2016 to $483 M YTD 2017. Number of deals increased from 65 to 102 in the same period. Largest disclosed private deals in 2017 we
Ackrell Capital Cannabis Investment Report – Terpene Benefits Overview (Dec 2017)
The passage is a generic industry report describing terpene profiles and alleged medicinal benefits. It contains no references to high‑profile individuals, government agencies, financial transactions, Describes therapeutic claims for various cannabis terpenes (myrcene, pinene, limonene, camphene). Provides a table of purported medical benefits (antianxiety, anti‑inflammatory, etc.). Published by A
Ackrell Capital Cannabis Investment Report – Terpene Profile (Dec 2017)
The document is a technical cannabis industry report containing terpene percentages and formulation data. It mentions no high‑profile individuals, government agencies, financial transactions, or contr Provides typical terpene composition percentages for cannabis flower. Describes the concept of the “Entourage Effect” and THC:CBD ratio ranges. Published by Ackrell Capital, a FINRA/SIPC‑registered f
Ackrell Capital Cannabis Investment Report – Technical Overview of CBDA and Decarboxylation (Dec 2017)
The passage is a purely scientific/financial overview of cannabinoid chemistry and investment context. It contains no mention of political figures, government agencies, financial flows tied to powerfu Describes CBDA as a non‑psychoactive precursor to CBD with potential medical benefits. Notes recent cultivation of cannabis strains with high CBDA levels comparable to THC. Explains decarboxylation p
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.